A Study Of IMM47 In Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-01-23
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH), open-label, multi-center, phase I study to evaluate the
safety, tolerance, pharmacokinetics (PK), immunogenicity, preliminary anti-tumor activity,
pharmacodynamics, and biomarker activity of IMM47 monotherapy in subjects with advanced solid
tumors.